Targets › NTRK
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on NTRK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Avistone Biotechnology | ANS03 ROS1 and NTRK tyrosine kinase inhibitor | ROS1, NTRK | Phase 1 | Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration | Dec 2027 |
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.